Leukocyte profiles in blood and CSF distinguish neurosarcoidosis from multiple sclerosis.
Adolescent
Adult
Aged
CD4-Positive T-Lymphocytes
/ immunology
Cell Separation
Central Nervous System Diseases
/ blood
Diagnosis, Differential
Female
Flow Cytometry
Humans
Leukocyte Count
Leukocytes
Lymphocyte Activation
Male
Middle Aged
Models, Immunological
Multiple Sclerosis
/ blood
Retrospective Studies
Sarcoidosis
/ blood
Young Adult
Flow cytometry
Immune cell profile
Multiple sclerosis
Neuroinflammation
Neurosarcoidosis
Journal
Journal of neuroimmunology
ISSN: 1872-8421
Titre abrégé: J Neuroimmunol
Pays: Netherlands
ID NLM: 8109498
Informations de publication
Date de publication:
15 04 2020
15 04 2020
Historique:
received:
11
11
2019
revised:
13
01
2020
accepted:
25
01
2020
pubmed:
3
2
2020
medline:
4
9
2020
entrez:
3
2
2020
Statut:
ppublish
Résumé
Distinguishing neurosarcoidosis (NS) from multiple sclerosis (MS) remains challenging and available parameters lack discriminatory power. Comprehensive flow cytometry data of blood and CSF leukocytes of patients with NS (n = 24), MS (n = 49) and idiopathic intracranial hypertension (IIH, n = 52) were analyzed by machine learning algorithms. NS featured a specific immune cell pattern with increased activated CD4+ T cells in CSF and increased plasma cells in blood. Combining blood and CSF parameters improved the differentiation. We thereby identify and independently validate a multi-dimensional model of blood and CSF supporting the difficult differential diagnosis between NS and MS.
Identifiants
pubmed: 32007787
pii: S0165-5728(19)30588-0
doi: 10.1016/j.jneuroim.2020.577171
pii:
doi:
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
577171Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest CCG received personal fees from Biogen, Genzyme, Novartis Pharma GmbH and Bayer Health Care. HW received personal fees from Abbvie, Actelion, Alexion, Biogen, Cognomed, Evgen, Sanofi Genzyme, Impulze, KWHC, MedDay Pharmaceuticals, Merck Serono, Novartis, PeerVoice, Pennside, PSL Group and Roche. HW also received research support from Biogen, Sanofi Genzyme, GlaxoSmithKline, Roche and Solace Pharmaceutical UK. LK has received personal fees and/or grants from Biogen, Genzyme, Novartis, Roche and Sanofi-Aventis. GMzH has received personal fees from LFB Pharma and Alexion Pharma. The remaining authors declare no financial or other conflicts of interest.